PMID- 9415647
OWN - NLM
STAT- MEDLINE
DCOM- 19980205
LR  - 20161124
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 24
IP  - 12
DP  - 1997 Dec
TI  - Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumor 
      necrosis factor-alpha expression in a mononuclear cell line.
PG  - 2385-8
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) is thought to be important in 
      chronic inflammation of joints characteristic of crystal induced arthritis. 
      Monocytes are instrumental in maintaining that inflammation. We investigated 
      production of mRNA and protein for TNF-alpha in vitro in a murine mononuclear 
      cell line, after exposure to relevant crystal types. METHODS: Using the cell line 
      designated RAW 264.7, cells were grown in standard medium and exposed to varying 
      amounts of monosodium urate (MSU), hydroxyapatite (HA), and calcium pyrophosphate 
      dihydrate (CPPD) crystals for differing time periods. Analysis of TNF-alpha mRNA 
      induced by such exposure was by Northern hybridization; analysis of TNF-alpha 
      protein was by ELISA: RESULTS: RNA analyses of cells treated with various levels 
      of MSU, HA, and CPPD crystals showed strong induction of TNF-alpha transcripts. 
      ELISA on culture supernatants confirmed high level TNF-alpha peptide secretion 
      resulting from that transcriptional upregulation. Time course studies showed peak 
      accumulation of TNF-alpha mRNA 1-6 h post-treatment. Study of the signalling 
      pathway involved in TNF-alpha transcriptional upregulation indicated that 
      increased phospholipase A2 activity was required. CONCLUSION: These observations 
      suggest that crystals in joints can directly stimulate production of TNF-alpha, 
      and that the source of that cytokine may be the monocytes known to be present and 
      playing an important role in chronic joint disease.
FAU - Meng, Z H
AU  - Meng ZH
AD  - Arthritis-Immunology Center, Medical Research Service, Philadelphia DVA Medical 
      Center, PA 19104, USA.
FAU - Hudson, A P
AU  - Hudson AP
FAU - Schumacher, H R Jr
AU  - Schumacher HR Jr
FAU - Baker, J F
AU  - Baker JF
FAU - Baker, D G
AU  - Baker DG
LA  - eng
GR  - AR-42541/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Acetophenones)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 268B43MJ25 (Uric Acid)
RN  - 91D9GV0Z28 (Durapatite)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - PN0FRW1G4Z (4-bromophenacyl bromide)
RN  - X69NU20D19 (Calcium Pyrophosphate)
SB  - IM
MH  - Acetophenones/pharmacology
MH  - Animals
MH  - Calcium Pyrophosphate/chemistry/*pharmacology
MH  - Cell Line
MH  - Crystallization
MH  - Durapatite/chemistry/*pharmacology
MH  - Enzyme Inhibitors/pharmacology
MH  - Gene Expression Regulation/drug effects/immunology
MH  - Mice
MH  - Monocytes/cytology/*drug effects/enzymology
MH  - Osteoarthritis/immunology/metabolism
MH  - Phospholipases A/antagonists & inhibitors/metabolism
MH  - Phospholipases A2
MH  - RNA, Messenger/metabolism
MH  - Signal Transduction/immunology
MH  - Transcription, Genetic/drug effects/immunology
MH  - Tumor Necrosis Factor-alpha/*genetics/metabolism
MH  - Uric Acid/chemistry/*pharmacology
EDAT- 1998/02/07 08:34
MHDA- 2001/03/28 10:01
CRDT- 1998/02/07 08:34
PHST- 1998/02/07 08:34 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1998/02/07 08:34 [entrez]
PST - ppublish
SO  - J Rheumatol. 1997 Dec;24(12):2385-8.